In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas

Scientific Reports

Volumn 5, Issue , 2015, Pages

  De Boer, Esther ^a,b   Warram, Jason M ^a   Tucker, Matthew D ^a   Hartman, Yolanda E ^a   Moore, Lindsay S ^a   De Jong, Johannes S ^c   Chung, Thomas K ^a   Korb, Melissa L ^a   Zinn, Kurt R ^d   Van Dam, Gooitzen M ^b   Rosenthal, Eben L ^a   Brandwein Gensler, Margaret S ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; INDOLE DERIVATIVE; IRDYE800;

FLUORESCENCE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CETUXIMAB; FLUORESCENCE; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MULTIVARIATE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84934288980     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10169     Document Type: Article

References (20)

1. Scott, A. M., Allison, J. P., Wolchok, J. D. Monoclonal antibodies in cancer therapy. Cancer Immun. 12, 14-21 (2012).
2. Waldmann, T. A. Immunotherapy: past, present and future. Nat. Med. 9, 269-277 (2003).
3. Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J. & Chatal, J. F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834 (2006).
4. Pastan, I., Hassan, R., Fitzgerald, D. J. & Kreitman, R. J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-565 (2006).
5. Grandis, J. R., Tweardy, D. J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 15, 3579-3584 (1993).
6. Fung, C., Grandis, J. R. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin. Emerg. Drugs 3, 355-373 (2010).
7. Bonner, J. A. et al. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin. Radiat. Oncol. 12, 11-20 (2002).
8. Mehra, R., Cohen, R. B., Burtness, B. A. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin. Adv. Hematol. Oncol. 10, 742-750 (2008).
9. Song, J. I., Grandis, J. R. STAT signaling in head and neck cancer. Oncogene 21, 2489-2495 (2000).
10. Agulnik, M. et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J. Clin. Oncol. 16, 2184-2190 (2007).
11. Zinn, K. R. et al. IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques. Mol. Imaging Biol. 1, 49-57 (2015).
12. Dei Tos, A. P. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int. J. Biol. Markers 4, S3-S9 (2007).
13. Gusterson, B. A., Hunter, K. D. Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol. 5, 522-527 (2009).
14. Boonstra, J., De Laat, S. W., Ponec, M. Epidermal growth factor receptor expression related to differentiation capacity in normal and transformed keratinocytes. Exp. Cell. Res. 2, 421-433 (1985).
15. Keereweer, S. et al. Optical image-guided cancer surgery: challenges and limitations. Clin. Cancer Res. 14, 3745-3754 (2013).
16. Brodell, L. A., Hepper, D., Lind, A., Gru, A. A., Anadkat, M. J. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J. Cutan. Pathol. 10, 865-870 (2013).
17. Takata, T., Tarutani, M., Zouboulis, C. C., Sano, S. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. J. Dermatol. Sci. 2, 165-168 (2012).
18. Terwisscha van Scheltinga, A. G. et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J. Nucl. Med. 11, 1778-85 (2011).
19. Heath, C. H. et al. Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice. Otolaryngol. Head Neck Surg. 2013 6, 982-990 (2013).
20. Shah, N. et al. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol. Imaging Biol. 2, 237-44 (2012).